Layer Slider

Slide backgroundSlide thumbnail
Slide backgroundSlide thumbnail
Slide backgroundSlide thumbnail

Slide backgroundTeamTeamTeam
Slide backgroundResearch TextResearch Text
Slide backgroundSlide thumbnail

Slide backgroundCell2Cell2
Slide backgroundVision1
Slide backgroundVideo2Video2

Research

Research

NewsPage

Clinical Support

Latest News

ICON L

Anti-Tumor Effect of Ascorbic Acid, Lysine, Proline, Arginine, and Green Tea Extract on Bladder Cancer Cell Line T-24

M.W. Roomi, V. Ivanonv, T. Kalinovsky, A. Niedzwiecki, M. Rath
International Journal of Urology 2006, 13(4): 415-419.

Aims:
Bladder cancer, the fourth incident cancer in men and tenth in women, is associated with a high rate of recurrence, even when treated in situ, and prognosis is poor once the cancer metastasizes to distant sites. Based on anticancer properties, we investigated the effect of a mixture of lysine, proline, arginine, ascorbic acid, and green tea extract on human bladder cancer cells T-24 by measuring: proliferation, MMP expression, and cancer cell invasive potential.

Methods:
Human bladder cancer cells T-24 (ATCC) were grown in McCoy medium supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 mg/ml) in 24-well tissue culture plates. At near confluence, the cells were treated with the nutrient mixture (NM) dissolved in media and tested at 0, 10, 50, 100, 500, and 1000 mg/ml in triplicate at each dose. Cells were also treated with PMA 200 ng/ml to study enhanced MMP-9 activity. Cell proliferation was evaluated by MTT assay, MMP activity by gelatinase zymography, and invasion through Matrigel.

Results:
NM inhibited the T-24 cell secretion of MMP-2 and 9, with virtual total inhibition of MMP-2 at 500 mg/ml and MMP-9 at 100 µg/ml concentration. The nutrient mixture significantly reduced the invasion of human bladder cancer cells T-24 through Matrigel in a dose-dependent fashion, with 95% inhibition at 500 µg/ml and 100% at 1000 µg/ml NM (p<0.001).

Conclusion:
Our results suggest that NM is an excellent candidate for therapeutic use in the treatment of bladder cancer, by inhibiting critical steps in cancer development and spread, such as MMP secretion and invasion.